SRC and chronic myelogenous leukemia, BCR-ABL1 positive: As the specific inhibitor of Src, Dasatinib has been approved for the treatment of chronic myeloid leukemia (CML), and it is now being evaluated for the clinical use in lung cancer [10,11].